Immunotherapy with antibodies against cytotoxic T-lymphocyte-associated protein 4 (CTLA4), programmed death-1(PD-1), and PD-L1 has been shown to be clinically effective and is used in treating various types of cancers [15–19]. Here, CTLA4 is linked to cancer.